(Q46399717)

English

Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib

scientific article published in May 2005

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

phase II clinical trial

0 references

phase I clinical trial

0 references

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

author name string

David Marin

1

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

Jaspal S Kaeda

2

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

Catharina Andreasson

3

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

Sue M Saunders

4

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

Marco Bua

5

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

Eduardo Olavarria

6

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

John M Goldman

7

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

Jane F Apperley

8

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

language of work or name

0 references

publication date

1 May 2005

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

103

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

9

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

1850-1855

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival of patients with chronic-phase chronic myeloid leukaemia on imatinib after failure on interferon alfa

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibition of Translation in Eukaryotic Systems by Harringtonine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20975

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.20975

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 December 2017

http://europepmc.org/abstract/MED/15786422

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46399717&oldid=2109644577"